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ABSTRACT: Sulfonamides are profoundly important in pharmaceutical design. C-N cross-coupling of sulfonamides is an effec-
tive method for fragment coupling and SAR mining. However, cross-coupling of the important N-arylsulfonamide pharmacophore 
has been notably unsuccessful. Here, we present a solution to this problem via oxidative Cu-catalysis (Chan–Lam cross-coupling). 
Mechanistic insight has allowed the discovery and refinement of an effective cationic Cu catalyst to facilitate the practical and scal-
able Chan–Lam N-arylation of primary and secondary N-arylsulfonamides at room temperature. We also demonstrate utility in the 
large scale synthesis of a key intermediate to a clinical HCV treatment.  
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The N-aryl sulfonamide functional group is ubiquitous in 
medicinal chemistry, with the value of this motif demonstrated 
in marketed drugs for many different disease indications 
(Scheme 1a).1 The broad utility of this group arises from the 
tetrahedral geometry, permitting control of H-bond do-
nor/acceptor directionality to more effectively interact with a 
target ligand, and the imbued modulation of physicochemical 
properties that can be used to influence pharmacokinetics.1 
N-Arylation of N-arylsulfonamides is an attractive approach 
to target synthesis, enabling an alternative fragment coupling 
to N-sulfonylation (which is not always straightforward due to 
the poor nucleophilicity of diarylamines), and also providing a 
platform for rapid SAR analysis. Despite its appeal, this has 
been a challenging process to realize via transition metal ca-
talysis.2 To the best of our knowledge, only two examples of 
Pd-catalyzed arylation of N-arylsulfonamides have been re-
ported (Scheme 1b),3 with ligand development usually re-
quired for substrates of impaired Lewis basicity.4 Ullman-
based approaches are generally limited to simple substrates 
based on the forcing conditions required.5 Oxidative cross-
coupling using Cu-catalysis (Chan–Lam cross-coupling) offers 
an appealing alternative based on the generally inexpensive, 
ligand-free, and mild reaction conditions prevalent in this area, 
as well as the availability and variety of organoboron coupling 
partners.6 However, Chan–Lam N-arylation of N-
arylsulfonamides is particularly underdeveloped: only scat-
tered examples are reported in the patent literature, with either 
low or no yields disclosed.7,8 Perhaps more importantly, the 
origin of the problem is unknown. Here, we provide a mecha-
nistically informed rationally designed system for practical 
and scalable Chan–Lam N-arylation of sulfonamides at room 
temperature (Scheme 1c). 
 
Scheme 1. (a) Exemplar sulfonamides in active pharmaceutical 
ingredients. (b) Previous Pd- and Cu-mediated N-arylsulfonamide 
N-arylation. (c) A mechanistically-informed Chan–Lam N-
arylation of N-arylsulfonamides. 
 
We recently reported a functional description of Chan–Lam 
amination (Scheme 2).9 The description was based on the most 
common reaction conditions using Cu(OAc)2 and Et3N as a 
base. The process is initiated by denucleation of the paddle-
wheel dimer to the catalytically active monomeric 
Cu(II)(R2NH) complex 1. Transmetalation of the organoboron 
reagent delivers Cu(II)(Ar)(R2NH) complex 2, which is oxi-
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dized via disproportionation to Cu(III) complex 3.10 Reductive 
elimination liberates the product and Cu(I). Completion of the 
catalytic cycle requires oxidation of Cu(I) to Cu(II), typically 
achieved by O2. 
 
Scheme 2. Key mechanistic considerations for reaction design. 
From mechanistic analysis, two N-substrate-dependent 
events were identified as critical: (1) the initial paddlewheel 
denucleation is highly dependent on the Lewis basicity of the 
N-substrate (Scheme 2a).9 (2) Similarly, N-substrate associa-
tion facilitates the oxidative turnover of the Cu catalyst 
(Scheme 2b).9 Efficient Cu(I) oxidation is essential not only 
for turnover but also to avoid organoboron oxidation, protode-
boronation, and homocoupling, which are driven by Cu(I).9 (1) 
and (2) were anticipated to be the difficult steps in sulfona-
mide N-arylation based on the poor Lewis basicity of the N-
arylsulfonamide. From the organoboron perspective, no spe-
cific issues were anticipated with arylboronic acids; however, 
use of BPin derivatives could lead to catalyst inhibition by 
pinacol (forming 4), generated from transmetalation byprod-
ucts (Scheme 2c).9 
Our reaction design was based on several considerations: 
(1) To aid paddlewheel denucleation, we selected a Cu(I) cata-
lyst without competing ligating anions (e.g., AcO–); 
Cu(MeCN)4PF6.11 This catalyst also served to reduce the quan-
tity of uncontrolled H2O in the system ([Cu(OAc)2]2 is usually 
the dihydrate), avoiding the need for rigorous drying and com-
peting organoboron oxidation.12 (2) Bolstering substrate liga-
tion would aid productive catalysis, avoid organoboron homo-
coupling, and facilitate oxidative turnover.9 N-
Arylsulfonamide deprotonation was identified as a simple 
solution. However, base selection would be crucial: the base 
must deprotonate without causing competing processes – di-
mer-forming anionic bases would therefore be incompatible 
based on the points above. A second concern was inhibition of 
transmetallation by boron speciation, which would be a greater 
problem for boronic acids than BPin esters based on the pro-
pensities for hydroxy- and ternary boronate formation.13,14 As 
such, we excluded anionic O-bases for boronic acid couplings 
and instead focused on amine bases. Anionic O-bases have 
shown some potential utility for Chan–Lam amination of 
Bpin,9 and are anticipated to be tolerated for Bpin due to a 
lower propensity for boronate formation.14 A greater base 
strength would help to avoid catalyst inhibition by pinacol by 
providing a greater solution concentration of substrate anion. 
Finally, adventitious desiccant effects using hygroscopic inor-
ganic bases would lower organoboron oxidation further.15 
Based on all of these considerations, we selected K3PO4 for 
Bpin processes. 
This mechanistic rationalization was successful on applica-
tion (Table 1). Using sulfonamide 5 as a benchmark substrate, 
control reactions with Cu(OAc)2 and Et3N confirmed the ary-
lation efficiency problem under standard conditions (entry 1). 
Moving to Cu(MeCN)4PF6 with Et3N immediately improved 
the reaction to deliver 57% and 18% yield using 6a and 6b, 
respectively (entry 2). Use of a stronger amine base (N-
methylpiperidine) delivered a highly effective process using 
6a (80%) and increasing base stoichiometry improved the 
yield further to 98% (entry 4). As expected from our previous 
work,9 amine bases gave a notably poorer performance with 
6b, due to catalyst inhibition by pinacol (ca. 20%; entries 3 
and 4). However, K3PO4 delivered 7a in 50% using 6b (entry 
5) with increased stoichiometry improving to 80% (entry 6). 
As anticipated, K3PO4 was significantly detrimental to the 
reaction of 6a (entries 5 and 6). All of these reaction parame-
ters were further investigated in multivariate arrays, confirm-
ing the optimal conditions from Table 1 (see Supporting In-
formation (SI) for full details). Several points are worth not-
ing: (1) the use of 0.5 equiv Cu was necessary for efficiency 
since Cu is required as catalyst and oxidant (oxidation of 
Cu(II)→Cu(III) and Cu(I)→Cu(II)); (2) the organoboron was 
required in excess to maintain efficiency with respect to the 
expected competing side reactions (i.e., protodeboronation, 
oxidation, and homocoupling); (3) selected inorganic bases 
were effective for reactions of 6a when used in in conjunction 
with Cu(OAc)2; however, these were not transferable to 6b.     
Table 1. Reaction optimization. 
  
Entry Conditions 7a from 
6a (%)a 
7a from 
6b (%)a 
1 Cu(OAc)2 (0.5 equiv), Et3N (6 equiv) 43 13 
2 Cu(MeCN)4PF6 (0.5 equiv), Et3N (6 
equiv) 
57 18 
3 Cu(MeCN)4PF6 (0.5 equiv), N-
methylpiperidine (6 equiv) 
80 21 
4 Cu(MeCN)4PF6 (0.5 equiv), N-
methylpiperidine (8 equiv) 
98 17 
5 Cu(MeCN)4PF6 (0.5 equiv), K3PO4 (3 
equiv) 
40 50 
6 Cu(MeCN)4PF6 (0.5 equiv), K3PO4 (8 
equiv) 
32 80 
a Conversion to product determined by HPLC. See SI. 
The origin of the efficiency gain from a mechanistic per-
spective was reinforced by spectroscopy (Figure 2). EPR anal-
ysis confirmed the denucleation problem (Figure 2a). Effective 
denucleation only takes place upon inclusion of a base capable 
of deprotonating 5. N-Methylpiperidine and K3PO4 were sig-
nificantly more effective than Et3N. Similarly, UV-Vis analy-
sis showed that Cu(I) oxidation is more effective with 5 in the 
presence of N-methylpiperidine and K3PO4 due to greater elec-
tron-density at Cu(I) (Scheme 2b). It is worthwhile noting that 
the oxidation using K3PO4 is slower than N-methylpiperidine 
due to the formation of some Cu(I)PO4 in situ.16 This further 
highlights the need to consider all potential substrate-catalyst 
and reagent-catalyst interactions in the design of these pro-
cesses (Figure 2b).  
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Figure 2. (a) Denucleation EPR analysis. (b) Cu(I) oxidation UV-
Vis analysis. NMP = N-methylpiperidine. 
 
The generality of the protocols was assessed by application 
to a series of substrates on 1 mmol scale (Scheme 3). Both 
protocols were broadly tolerant of functionality on the organo-
boron partner including variation of regiochemistry and elec-
tronic character, as well as the functionality on the N-aryl sul-
fonamide arene and the sulfonyl group. In particular, halide 
substituents (e.g., 7l, 7n, 7x) reinforce the orthogonality of the 
Chan–Lam amination with respect to redox neutral Pd and Cu 
methods, retaining these handles for subsequent manipulation. 
This key feature was important to the subsequent application 
of this method in target synthesis (vide infra). Notably, this 
protocol was chemoselective for the sulfonamide N-arylation 
vs. carbamate N-arylation (7k). While the focus of this study 
was to enable N-aryl sulfonamide N-arylation, we found the 
protocol amenable to arylation of both primary and N-alkyl 
sulfonamides, thereby establishing a broadly applicable meth-
od for sulfonamide arylation. Important to our focus on devel-
oping a practical methodology, the reaction operates at ambi-
ent temperature and using O2 from air (instead of, for example, 
a saturated O2 atmosphere). Yields were synthetically useful in 
the main, with sensitive organoborons (e.g., heterocyclic ex-
amples 7j, 7l, 7v, 7w) and primary sulfonamides (7p, 7s, 7t) 
the most challenging. 
 
Scheme 3. N-Arylation scope. 1 mmol scale (sulfonamide), ex-
cept for 7a and 7q, which are on 20 mmol scale. Isolated yields. 
Similarly, our objectives required the development of a 
scalable process. To this end, the method was found to operate 
effectively on 20 mmol (3.4 g sulfonamide) scale for two ex-
amples (7a and 7q, Scheme 3). The products were isolated in 
high purity (>98% purity), with the reaction to form 7a requir-
ing only a simple aqueous wash (NH4OH, NH4Cl) procedure. 
These results demonstrate the potential power of this Chan–
Lam protocol not only for medicinal chemistry analogue gen-
eration and SAR, but also for eventual scale-up of potential 
clinical candidates.  
As a final demonstration of utility, we report the use of this 
Chan–Lam coupling as a key transformation in the synthesis 
of the NS5B inhibitor GSK8175 (Scheme 4).7c NS5B inhibi-
tors block the RNA polymerase activity of the NS5B viral 
enzyme and are an important class of hepatitis C (HCV) thera-
peutics.17 HCV is a life-threatening condition with no known 
vaccine affecting approximately 2% of the global population,18 
with the majority of cases occurring in the developing world. 
Accordingly, the development of effective treatments for HCV 
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 4 
is a major international goal. A key structural feature of 
GSK8175 is the N,N-diarylsulfonamide, and the accompany-
ing boronate ester moiety. Application of this Chan–Lam 
chemistry as an orthogonal coupling approach allows use of 
the halogenated aryl substrate 9 to access compound 10, which 
can be quickly elaborated to the API.7c While our general con-
ditions were found to be broadly effective on 1-20 mmol scale 
(Scheme 3), some optimization was necessary on this more 
challenging substrate. Specifically, targeted optimization led 
to several modifications for this specific transformation, in-
cluding use of NEt3 (to generate a soluble triethylammonium 
carboxylate in situ) and a dilute 5% O2 stream as the terminal 
oxidant (to maintain a basis of safety on large scale). With 
these modifications to our general protocol, we have achieved 
63% isolated yield of 10 on 15 g scale after crystallization of 
the methylammonium salt.19  
 
 
Scheme 4. N-Arylsulfonamide N-arylation en route to GSK8175. 
Isolated yield. 
 
In summary, rational methodological design enabled by 
mechanistic insight has allowed the development of an effec-
tive protocol for Chan–Lam arylation of a variety of primary 
and secondary sulfonamides. The mild reaction conditions 
operate effectively on small (1 mmol) scale and can be readily 
scaled (20 mmol and above). This methodology is facilitating 
the large-scale production of a clinical HCV therapy and we 
expect similar utility to be found in other applications in 
pharmaceutical development. 
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